Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Deals are to be announced soon. Wall Street is going to fall in love with LWLG. LWLG is the ultimate rapid growth opportunity in one of the hottest sectors, namely AI. Over the next couple of years, we will see a hockey stick stock chart pattern begin to emerge. Ubiquity has its perks! It's real, and it's happening! Boom!!
Hidden gem. They have VOIP patents all upheld against all IPR challenges and zero claims removed. Actually, 7 or 8 claims were added... This is a 2–5 billion-dollar MCAP all day long.
Begi is definitely big!
Seeing tactics from bashers is sad, but it also reinforces the strong beliefs in this new era of trading.
There’s people that want to build in life.
For a better future
And there’s those trying to live off our hard word.
How miserable some people’s lives must be when you have lost all guidelines to becoming a better person.
Go get some coffee for the lings, Pedro! If it’s not too hard for you,!
I love the daily volume, which is normally over 1 million shares per day. The new peeps on the message boards signify we have something special in ELTP, which is good, or they wouldn't be here. The last will be sink or swim, and I believe we have a winner.
Nothing is 100% certain, but here's a non-exhaustive list of things within 12 months. I have 80% plus confidence that Blarcamesine is approved for Rett. First Blarcamesine sales for Rett happen Blarcamesine is approved for Alzheimer's in Europe. 3-71 shows continued success and promise. The market cap exceeds $2.5 billion.
Positive cash flow from operations and $57 million in cash during the company’s development stage. Applause to CT. $12 million share repurchase and new wallet inbound shortly.
All I want for Christmas is FDA Accelerated Approval. Is that too much to ask? Missling, don't be a grinch!
The news this week makes it explode.
A quick reminder: we were at $11 just a month ago, prior to the best earnings ever and then dilution news (which still hasn't happened yet). I think a return to the $9–$11 range is very likely in the next month or so.
It is primed for another run soon, it seems.
Shorties tried to push back hard below 200 SMA today to make a case, but to no avail. 18 million short shares are trapped, and all their efforts to squirm out of the long grasp will be useless without pay. I am still waiting for the epic short squeeze that is surely coming.
The price always starts positive but ends negative. Hopefully, the sentiment will change as we get closer to the end of the year.
I am super stoked for the longs here that have weathered the extreme emotional roller-coaster ride Nortwest has endured. Regardless of what the share price does over the coming weeks, the insider purchase is significant and cannot be seen as anything but bullish. Godspeed bulls
Imo, > 50% for a PR at 9 a.m. sharp today.
Did you see what Neximmune did? And they are nothing. Investors are hungry for the next 10–20x gapper. NWBO is that stock. Once MHRA filing shorts get and stars align for generational wealth, and btw, we help cancer patients live longer!
At some point in the future, people will wish they had gotten in at this price. All my opinions
Positive fundamental data or growth will drive the price up over time. Nothing goes straight up. We need to ignore day-to-day volatility. Another example is bitcoin. extremely volatile and, at the same time, highly profitable for long-term holders.
There are a lot of bashers that just want to pay less. This company is an actual company with SEC filings, financials, a real and experienced CEO, and a patent. I'm not selling and will buy more.
We must be getting right over the target. I’ve never seen such a multi-pronged, big-dollar-backed effort to harm a company. Naked and coordinated shorts, frivolous lawsuits that would actually harm the plaintiffs (via their lost investments) if successful, slanderous articles—and now it seems even academic researchers are on the take. When fighting WS billionaires and Big Pharma at the same time, it would make sense that this would happen only if what is at stake is a huge threat to the status quo.
Low chance but a solid ER call, Rett results, and peer review all within the next 2 weeks would send this sailing.
FNMA and FMCC Commons are two of those holdings where I'm convinced that I'm right, but so far I am horribly wrong. It's dangerous to have this because I keep holding and building it over time. Now my holdings are too big for a healthy portfolio.
I would love to hear a partnership announcement on Monday morning; you never know.
Anyone notice that the only licence this pathetic scam ever made (to Alphasigma), touting $24 million in biobucks, is now dead? Terminated. In fact, all of the deals made over the long, tortured history of this scam are terminated and gone. Every hyped-up press release was a scam that went nowhere. So to all the Darwin Awardees who continue to own this scam, keep buying because the price is low.
Extremely Bullish Outlook! "Let's look at 2023. In the last three quarters, from January until September, ELTP made more than $30 million. By the end of this quarter, by December, ELTP would be north of $40 million. Next year is going to be a bigger year because we will have Prasco in the mix. And later on in the year, we will have some of the needle movers as well. So next year, the calendar year 2024 will be even bigger than that. And for 2025, will it be even bigger than that, too, because most of the needle movers will get approval towards the end of the year? So what I'm looking at is an extremely positive outlook for Elite. The increase we have seen from $7.5 million to $23 million is only the beginning. I think the next three to four years are going to be fantastic for us and for the stockholders."CEO during the Q&A session from the latest conference call
While today’s PR was a bit confusing, if you read the previous PR and the current PR together, the logical conclusion is that the application is now in the hands of the publisher, and thanks to a poorly written PR that has been reacted to poorly, we’ve all been given a chance to buy some more at a discount.
On 8/28/23, Elite announced the success of the BE study done for $5.1 billion in drugs. Projected FDA approval in 2024:an undisclosed generic drug product in a class of medications called CNS stimulants. IQVIA reported annual sales for the twelve months ending June 2023 of $5.1 billion for the brand and generic market for this product."
AMC Market Cap: $1.461 Billion
It made $1.4 billion in revenue in Q3.
Has $1.19 billion in cash on hand,
How is the Sp $6?
We are at 66 percent lower than the pandemic shutdown. How?
Holding nice and steady today. Maybe we get good PR this week that everyone has been waiting on. Sure, it would be nice for a change.
This has potential. I could see our VPLM hitting national news one day.
Reverse merger plays are extremely profitable. This could see copper rather quickly, IMO.
Just read the 10Q cover to cover. Business is in rock-solid shape from where it's been. They need to continue to manage debt, but they've got ~ 12 quarters to do so. Their food and beverage margin is insane; > 90% of their leased assets provide iMax or recliner experience, and international markets look stronger than ever. Cinema is also a 'go-to' play in winter and a recession (vs. Disney, Six Flags, etc.). They've got breathing room around covenants and a decent handle on things. Say what you like, but it's grossly undervalued at $1.47 billion, IMO.
Yes, but still, it has a good quarter compared to HUT HIVE and WULF.
I bought more again.
I have massively increased my position this month. I do not see how DCVax isn't approved. Zero side effects. Published results in JAMA. Publications in Nature and SNO are forthcoming. Evidence of intuitional buying. And we are only weeks away from submission while we are trading on support.
OLB reported an excellent quarterly performance, with revenue of $9.69 million, up from $6.25 million the previous year. This represents a 55.2% increase over the previous year.
The net loss fell from $1,854,641 in the previous year's quarter to $1,833,049 this year. Aside from that, the business has begun the process of completing a spinoff of Dmint, its cryptocurrency mining operation, and when finished, the stock price will hit $1 before Christmas and $5 before mid-2024.
Stock has been in the 12–15 cents range but looks ready to breakout as next week's conference call should open eyes as to the potential for massive revenue increases due to manufacturing contracts with pyros and burel set to commence in 7 weeks. It is likely that the quota for Adderall, now set every 3 months, has been increased based on predictable usage by Elite. Next stop. 22-25 centavos. A double from here.
It will be awesome to see Anavex as one of the catalysts ushering excitement back into small biotech investing over the next nine months. Let's go!
It has always been an uphill battle with ELTP stock. Despite having positive earnings for the past 3 quarters and increasing revenues, the stock would still go down until the last quarter. The future has more positive events that make me a holder until Nasrat can prove me wrong. The market makers or some other entity can push the price around, but it's getting harder because the news and profits are heading north. To leave and sell out now would be a tragedy, so I'll wait a little longer and cheer this little train going forward.
So yesterday being Wednesday, I guess it's likely "golf day" for AVXL management, and Thursdays are "pickleball day". Friday is "weekend prep day". So this work week is over, and there is still no final data on the Alzheimer's P3 printout or news on the FDA filing. Maybe next week, but Monday is "show and tell day" for what everyone did on the weekend. That leaves Tuesday of next week open.
The warrants are worthless under the conservatorship. Either the conservatorship will end or the warrants will expire without being executed. Even if the share price remains constant after being executed, the warrants will only be worth $3.3 billion. Fannie alone makes more than that in a quarter. The government would spend more money selling them than they would make in proceeds.
There is likely some selling pressure at these prices. When the price spiked to 90 cents after the trial verdict, it instantly came back down. Many people made money buying in at 45 cents and selling at 90 cents. I'm in this for the long haul. I have been holding for years and will wait until C-ship is done. This will either be an eye-watering tax loss or something wonderful.